Business
Cannabics Pharmaceuticals Announces a New Dosage of 5mg THC Cannabis Capsule Treating Cancer Patients Suffering from Cachexia and Anorexia Syndrome
Cannabics Pharmaceuticals Announces a New Dosage of 5mg THC Cannabis Capsule Treating Cancer Patients Suffering from Cachexia and Anorexia Syndrome.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals Announces a New Dosage of 5mg THC Cannabis Capsule Treating Cancer Patients Suffering from Cachexia and Anorexia Syndrome\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals Announces a New Dosage of 5mg THC Cannabis Capsule Treating Cancer Patients Suffering from Cachexia and Anorexia Syndrome\nPR Newswire\nBETHESDA, Maryland, Jan. 3, 2017\n\n\n\nBETHESDA, Maryland, Jan. 3, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) today announced development of Cannabics 5mg THC Capsule intended for naïve patient who have not tried cannabis in the past.\n\n\n \n \n\n \nDr. Eyal Ballan, Chief scientist of Cannabics Pharmaceuticals stated, \"Our mission is to find the right balance between efficacy on the one hand and the elimination of undesired psychoactive effects on other.\" \n\nThe Cannabics 5mg THC capsule is currently being evaluated by the company in a clinical study as a palliative treatment, which is conducted by the oncology department at the prestigious Rambam Medical Center in northern Israel and under strict regulations of the Ministry of Health, by whom Cannabics Pharmaceuticals has been licensed since 2014.\n\nThe study is taking place in Israel, it is fully registered with the US NIH under \"Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients\", Identifier NCT02359123, and may be found at https://clinicaltrials.gov/ct2/show/NCT02359123 \n\n\"The majority of our cancer trial patients have no previous experience with Cannabis, hence this recalibration of the THC level may be more amenable. We believe there is a significant potential medical market for our 5mg THC capsule in countries that have now instituted medical cannabis regulations,\" said Itamar Borochov, CEO of Cannabics Pharmaceuticals Inc.\n\nAbout Cannabics Pharmaceuticals Inc. \n\nCannabics Pharmaceuticals Inc. (OTCQB: CNBX), a U.S based public company, is dedicated to the development of Personalized Anti-Cancer and Palliative treatments. The Company's R&D is based in Israel, where it is ...